Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TMB-607 in HIV-Negative Volunteers
NCT03110549Phase 1Terminated
- Sponsor
- TaiMed Biologics
- Start
- Nov 2016
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TMB-607 in human immunodeficiency virus infection (HIV) (7 cohorts), sponsored by TaiMed Biologics. Primary endpoint: TMB 607 plasma concentrations at 10 weeks. Started Nov 2016; status: terminated.
02
Drugs
TMB-607
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03110549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110549.